TECH
Bio-Techne Corporation
53.13
2 x 49.96
2 x 57.51
bid
ask
-
0.35
0.65%
2 @ 04:00 PM
53.13 +0.00 (0.00%)
Ytd -9.66%
1y -8.99%
51.36
day range
54.79
46.66
52 week range
71.38
Open 52.01 Prev Close 53.48 Low 51.36 High 54.79 Mkt Cap 8.31B
Vol 1.79M Avg Vol 2.44M EPS 0.53 P/E 100.25 Forward P/E 24.44
Beta 1.48 Short Ratio 5.20 Inst. Own 113.84% Dividend 0.32 Div Yield 0.60
Ex Div Date 02-13 Earning 05-06 50-d Avg 58.08 200-d Avg 57.71 1yr Est 74.91
Earning
Date For Estimate Reported Surprise surprise %
2026-05-06 2026-03 0.55 N/A N/A N/A
2026-02-04 2025-12 0.43 0.46 0.03 6.98%
2025-11-05 2025-09 0.42 0.36 -0.06 -14.29%
2025-11-05 2025-09 0.42 0.42 N/A N/A
2025-08-06 2025-06 0.5 0.53 0.03 6.00%
2025-08-06 2025-06 0.5 0.51 0.01 2.00%
Upgrade / Downgrade
Date Firm Action From To
2026-02-06 Wells Fargo Upgrade Overweight Overweight
2026-02-05 Citigroup Upgrade Buy Buy
2026-02-05 Stifel Upgrade Hold Hold
2026-02-05 TD Cowen Upgrade Buy Buy
2026-02-05 UBS Upgrade Buy Buy
2026-02-05 Evercore ISI Group Upgrade In-Line In-Line
Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Insider Holder
Date Name Relation Quantity Description
2025-10-29 BAUMGARTNER ROBERT V Director 46.50K Stock Award(Grant)
2025-10-29 BUSHMAN JULIE L. Director 8.78K Stock Award(Grant)
2025-11-02 GEIST WILLIAM Officer 20.50K Conversion of Exercise of derivative security
2025-10-29 HIGGINS JOHN L Director 66.88K Stock Award(Grant)
2025-11-02 HIPPEL JAMES Chief Financial Officer 142.72K Conversion of Exercise of derivative security
2025-10-29 KEEGAN JOSEPH D Director 15.41K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Vanguard Group Inc 17.81M 946.29M 11.38%
2025-12-30 Blackrock Inc. 12.13M 644.42M 7.75%
2025-12-30 Morgan Stanley 8.35M 443.39M 5.33%
2025-12-30 State Street Corporation 5.81M 308.79M 3.71%
2025-12-30 Wellington Management Group, LLP 5.73M 304.65M 3.67%
2025-12-30 Geode Capital Management, LLC 4.93M 261.92M 3.15%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 4.91M 261.06M 3.14%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 3.93M 208.75M 2.51%
2025-12-30 Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund 3.81M 202.34M 2.43%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund 3.54M 187.92M 2.26%
2026-01-30 VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund 2.72M 144.52M 1.74%
2026-01-30 Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF 2.62M 139.22M 1.67%
Dividend
Dividend Date
0.08 2026-02-13
0.08 2025-11-17
0.08 2025-08-18
0.08 2025-05-19
0.08 2025-02-14
0.08 2024-11-08
Split
Split Date
4 : 1 2022-11-30
2 : 1 2000-12-04
2 : 1 1997-11-18